Bedaquiline represents both a novel chemical class – diarylquinolines (DARQs) – as well as a novel M.tb-selective mechanism of action (direct inhibition of M.tb ATP synthase). This next-generation diarylquinoline project has shown potential to maintain bedaquiline’s impressive anti-TB activities while retaining additional improved properties.